MCID: VTL004
MIFTS: 48

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 malady

Categories: Genetic diseases, Rare diseases, Skin diseases, Immune diseases

Aliases & Classifications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

Aliases & Descriptions for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

Name: Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 49 11 24 65
Vitiligo 32 10 45 23 47 12 49 67 36 35 65
Generalized Vitiligo 67 65
Vtlg 23 67
 
Vitiligo-Associated Multiple Autoimmune Disease 1 67
Systemic Lupus Erythematosus Vitiligo-Related 67
Vamas1 67
Slev1 67

Characteristics:

HPO:

61
vitiligo-associated multiple autoimmune disease susceptibility 1:
Inheritance: polygenic inheritance


Classifications:



External Ids:

OMIM49 606579
Disease Ontology10 DOID:12306
ICD1027 L80
ICD9CM29 709.01
SNOMED-CT59 156437000, 56727007
NCIt42 C26915
UMLS65 C0042900, C1847835, C1304470

Summaries for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section
NIH Rare Diseases:45 Vitiligo is a pigmentation disorder in which melanocytes (the cells that make pigment) in the skin are destroyed. as a result, white patches appear on the skin in different parts of the body, and sometimes also on both the mucous membranes and the retina. the average age of onset is in the mid-20s. it is generally considered to be an autoimmune disorder, and about 20-25 percent of people with vitiligo also have at least one other autoimmune disorder. in the absence of other conditions, vitiligo does not affect general health; however, concerns about appearance and ethnic identity are significant issues for many affected individuals. the exact cause of vitiligo is not known, but there are several different theories. there is strong evidence that people with vitiligo inherit a group of genes that make them susceptible to depigmentation. the main goal of treating vitiligo is to improve appearance; current treatment options include medication, surgery, and adjunctive therapies (used along with surgical or medical treatments). last updated: 11/20/2012

MalaCards based summary: Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1, also known as vitiligo, is related to dyslexia and congenital deafness with vitiligo and achalasia, and has symptoms including vitiligoand nevus. An important gene associated with Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 is NLRP1 (NLR Family, Pyrin Domain Containing 1), and among its related pathways are Dopamine metabolism and CTLA4 Signaling. The drugs methoxsalen and trioxsalen have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and retina, and related mouse phenotypes are tumorigenesis and endocrine/exocrine gland.

Disease Ontology:10 A hypersensitivity reaction type II disease that causes depigmentation of patches of skin resulting from loss of function or death of melanoctyes.

UniProtKB/Swiss-Prot:67 Vitiligo: A pigmentary disorder of the skin and mucous membranes. It is characterized by circumscribed depigmented macules and patches, commonly on extensor aspects of extremities, on the face or neck and in skin folds. Vitiligo is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. It is a multifactorial disorder with a complex etiology probably including autoimmune mechanisms, and is associated with an elevated risk of other autoimmune diseases. Vitiligo-associated multiple autoimmune disease 1: A disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.

MedlinePlus:35 Vitiligo causes white patches on your skin. it can also affect your eyes, mouth, and nose. it occurs when the cells that give your skin its color are destroyed. no one knows what destroys them. it is more common in people with autoimmune diseases, and it might run in families. it usually starts before age 40. the white patches are more common where your skin is exposed to the sun. in some cases, the patches spread. vitiligo can cause your hair to gray early. if you have dark skin, you may lose color inside your mouth. using sunscreen will help protect your skin, and cosmetics can cover up the patches. treatments for vitiligo include medicines, light therapy, and surgery. not every treatment is right for everyone. many have side effects. some take a long time. some do not always work. nih: national institute of arthritis and musculoskeletal and skin diseases

Genetics Home Reference:23 Vitiligo is a condition that causes patchy loss of skin coloring (pigmentation). The average age of onset of vitiligo is in the mid-twenties, but it can appear at any age. It tends to progress over time, with larger areas of the skin losing pigment. Some people with vitiligo also have patches of pigment loss affecting the hair on their scalp or body.

OMIM:49 Generalized vitiligo is an autoimmune disease characterized by melanocyte loss, which results in patchy depigmentation... (606579) more...

Wikipedia:68 Vitiligo is a chronic skin condition characterized by portions of the skin losing their pigment. It... more...

Description from OMIM:49 193200

Related Diseases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 625)
idRelated DiseaseScoreTop Affiliating Genes
1dyslexia30.6PMEL, TYR
2congenital deafness with vitiligo and achalasia12.5
3alopecia universalis onychodystrophy vitiligo12.4
4vitiligo mental retardation facial dysmorphism uremia12.3
5vitiligo-associated autoimmune disease12.3
6autoimmune disease 111.8
7alopecia areata11.6
8spastic paraplegia 2311.4
9schrander-stumpel theunissen hulsmans syndrome11.4
10waardenburg syndrome/ocular albinism, digenic10.6MITF, TYR
11idiopathic macular telangiectasia type 110.6MITF, TYR
12albinism, oculocutaneous, type ib10.5MITF, TYR
13pyloric stenosis, infantile hypertrophic, 310.5MITF, TYR
14melanoma, cutaneous malignant 810.5MITF, TYR
15plexiform schwannoma10.5PMEL, TYR
16autosomal dominant congenital stationary night blindness10.5AIRE, NLRP1
17skin benign neoplasm10.4MITF, PMEL, TYR
18androgen insensitivity syndrome, mild10.4CTLA4, PTPN22
19cutaneous lupus erythematosus10.4AIRE, POMC
20stiff-person syndrome10.4
21autoimmune polyglandular syndrome type 310.4
22congenital short femur10.4CAT, TPO
23miliary tuberculosis10.4AIRE, CTLA4, PTPN22
24pseudotyphus of california10.4PAH, PCBD1
25toxic maculopathy10.3CD8A, POMC
26intrahepatic gall duct cancer10.3CD8A, PTPN22, TYR, TYRP1
27breast cancer10.3
28thymus cancer10.3AIRE, CD8A, CTLA4
29congenital dyserythropoietic anemia10.3CD8A, PTPN22
30posterior mediastinum cancer10.3DCT, TYR, TYRP1
31olfactory nerve disease10.3KITLG, POMC
32hepatitis10.3
33macroglobulinemia, waldenstrom 110.3CD8A, CTLA4, PTPN22
34autoimmune-related retinopathy and optic neuropathy10.3AIRE, CTLA4, DDC
35anal margin basal cell carcinoma10.3MITF, MLANA
36anterior foramen magnum meningioma10.3MLANA, PMEL, TYR
37hashimoto thyroiditis10.3CTLA4, PTPN22, TPO
38inflamed seborrheic keratosis10.3MLANA, PMEL, TYR
39endotheliitis10.2
40immunodeficiency 7, tcr-alpha/beta deficient10.2
41autoimmune polyendocrinopathy syndrome , type i, with or without reversible metaphyseal dysplasia10.2
42piebaldism10.2
43progressive hemifacial atrophy10.2
44vogt-koyanagi-harada disease10.2
45facial hemiatrophy10.2
46skin pigmentation disorders10.2
47lelis syndrome10.2
48interstitial myocarditis10.2MITF, MLANA, PMEL
49meninges hemangiopericytoma10.2MLANA, PMEL, TYR
50malignant breast melanoma10.2MITF, MLANA, TYR

Graphical network of the top 20 diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:



Diseases related to vitiligo-associated multiple autoimmune disease susceptibility 1

Symptoms for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

Symptoms by clinical synopsis from OMIM:

193200

Clinical features from OMIM:

606579,193200

HPO human phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

id Description Frequency HPO Source Accession
1 vitiligo HP:0001045
2 nevus HP:0003764

Drugs & Therapeutics for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

Drugs for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 75)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
HyaluronanapprovedPhase 4, Phase 33629067-32-7, 9004-61-953477741, 24759
Synonyms:
Hyaluronate
Hyaluronic acid
Hyaluronic acid sodium salt
Hylartil
Hyruan Plus
Luronit
Macronan
 
Mucoitin
Nutra-HAF
Q 5AQ
Sepracoat
Sepragel Sinus
Sodium hyaluronate
Sofast
Synvisc
2
Fluocinolone Acetonideapproved, investigationalPhase 43967-73-26215
Synonyms:
(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide
6.Alpha., 9.alpha.-Difluoro-16.alpha.-h
6.Alpha.,9-Difluoro
6.alpha.,9-Difluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone
6.alpha.,9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide
6.alpha.-Fluorotriamcinolone acetonide
67-73-2
6a,9a-difluoro-16a-hydroxyprednisolone 16,17-acetonide
6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone
6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide
6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide
6alpha-Fluorotriamcinolone acetonide
AC-429
AC1L1M1L
AC1Q6ACL
AR-1H0758
Acetonida de fluocinolona
Acetonida de fluocinolona [INN-Spanish]
Acetonide de fluocinolone
Acetonide de fluocinolone [INN-French]
Acetonido de fluocinolona
Acetónida de fluocinolona
Acétonide de fluocinolone
C24H30F2O6
CCRIS 3250
CHEMBL989
CID6215
CPD000058329
Capex
Coriphate
Cortiplastol
D01825
DB00591
Derma-smoothe/fs
Dermalar
Dermatin (steroid)
Dermotic
EINECS 200-668-5
F0657
F8880_FLUKA
F8880_SIGMA
FLUOCINOLONE ACETONIDE
FS
Flucinar
Flucinolone
Flucort
Fluocet
Fluocet (TN)
Fluocinolon acetonid
Fluocinolonacetonid
Fluocinolonacetonidum
Fluocinolone 16,17-acetonide
Fluocinolone Acetonide
Fluocinolone Acetonide 0.01%
Fluocinolone acetonide (JP15/USP/INN)
 
Fluocinolone acetonide [DCIT]
Fluocinolone acetonide [USAN:INN:JAN]
Fluocinoloni acetonidum
Fluocinoloni acetonidum [INN-Latin]
Fluonid
Fluortriamcinolone Acetonide
Fluotrex
Fluovitif
Flupollon
Fluzon
Fs Shampoo
HMS2090I14
HSDB 3083
Iluvien
Jellin
LS-118443
Localyn
Localyn Syntex
MLS000028545
MLS001076276
Medidur
MolPort-002-528-328
NCGC00021301-04
NCI60_042042
NSC 92339
NSC92339
Neo-Synalar
Omniderm
Percutina
Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone
Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone
Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI)
Prodermin
RS 1401AT
RS-1401 AT
Radiocin
Retisert
Retisert (TN)
S2470_Selleck
SAM002564208
SMR000058329
STOCK1N-55828
Sinalar
Synalar
Synalar (TN)
Synalar Ts
Synalar-HP
Synamol
Synandone
Synandrone
Synemol
Synotic
Synsac
Tefunote
UNII-0CD5FD6S2M
WLN: T F5 E5 B666 GO IO RV AHTTTT&J A BF CQ E FVIQ H H OF -A&BHO -B&ACEF
ZINC03977981
component of Neo-Synalar
flucinolone
ydroxyprednisolone 16,17-acetonide
3
LidocaineapprovedPhase 4, Phase 31103137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Afterburn
Akten
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bikini Zone Medicated
Bikini Zone Medicated Creme
Bio-0767
Bio-scriptives Lidum
Bio-scriptives Lidum Hemorroidal (anorectal)
Bio-scriptives Lidum Topical Analgesic
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
Burn Relief Leader
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Comfortcaine
Cuivasil
Curacaine Transdermal Corporation
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
Derma Numb
DermaFlex
Desert Harvest Releveum
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Dr. Numb
Dr. Richs Numbing
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gigi Anesthetic Numbing
Gravocain
H-releve Hemorrhoidal
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
Hawaiian Tropic
Hush Anesthetic
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
LS-805
Lanabiotic
 
Laryng-o-jet
Leostesin
Lida-Mantle
Lidall
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine 4% Cream
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Hydrochloride
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocaine hydrochloride
Lidocainum
Lidocainum [INN-Latin]
Lidocare Mist
Lidocaton
Lidocream 4
Lidocream 5
Lidoderm
Lidoderm 5
Lidoject-1
Lidoject-2
Lifestyles Epic Male Genital Desensitizer
Lignocaine
Lignocainum
Lingocaine
Lmx4
Lmx5
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Numb Master Topical Anesthetic
Numb Nuts
Ocean Potion Instant Burn Relief Ice
Octocaine
Octocaine-100
Octocaine-50
Plum Smooth Plumb Numb Gelee
Premjact Male Desensitizer Pound International
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Recticare
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Simplicity Desensitizing
Simply Numb Endure
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Sole Serum
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Walgreens Aloe Vera Pain Relieving
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocaine-mpf
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zcaine Fast Acting Anesthetic
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
4
Pimecrolimusapproved, investigationalPhase 4, Phase 260137071-32-06447131, 17753757
Synonyms:
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-3-((E)-2-((1R,3R,4S)-4-chloro-3-methoxycyclohexyl)-1-methylvinyl)-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,26,26a-hexadecahydro-5,19-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,17,20,21(4H,23H)-tetrone
137071-32-0
33-Epi-chloro-33-desoxyascomycin
33-epi-Chloro-33-desoxyascomycin
ASM 981
ASM-981
ASM-998
CHEMBL1200686
CID6447131
CID6509979
CID6916008
D05480
DB00337
 
Elidel
Elidel (TN)
I06-1252
LS-181798
MolPort-003-666-749
NCGC00167506-01
Pimecrolimus
Pimecrolimus (JAN/USAN/INN)
Pimecrolimus [USAN:INN:BAN]
Pimecrolimusum
S5004_Selleck
SDZ ASM 981
SDZ-ASM 981
SDZ-ASM-981
UNII-7KYV510875
5
Tacrolimusapproved, investigationalPhase 4, Phase 3, Phase 21023104987-11-3445643, 439492, 445647
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
8-DEETHYL-8-[but-3-enyl]-ascomycin
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
FR900506
 
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
Hecoria
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus Hydrate
Tacrolimus anhydrous
Tacrolimus hydrate
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
6
Tretinoinapproved, investigational, nutraceuticalPhase 4210302-79-45538, 444795
Synonyms:
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
.beta.-Retinoic acid
13497-05-7 (hydrochloride salt)
15-Apo-beta-caroten-15-oic acid
187175-63-9
1n4h
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
302-79-4
5300-03-8
56573-65-0
7005-78-9
9(Z)-Retinoic acid
9-cis-RA
A-Acido (Argentina)
A-Vitaminsyre
A-Vitaminsyre [Denmark]
AC-6824
AC1L9GWO
AC1Q1J2J
AGN 100335
AGN 192013
AKOS000280845
ALRT 1057
AT-RA
ATRA
Aberel
Aberela
Aberela [Norway]
Accutane Roche
Acid A Vit (Belgium, Netherlands)
Acid, Retinoic
Acid, Vitamin A
Acid, all-trans-Retinoic
Acid, beta-all-trans-Retinoic
Acid, trans-Retinoic
Acide retinoique (French)
Acide retinoique (French) (DSL)
Acide retinoique (french) (dsl)
Acnavit
Acnavit [Denmark]
Airol
Aknefug
Aknoten
Alitretinoin
All Trans Retinoic Acid
All Trans-Retinoic Acid
All-(E)-Retinoate
All-(E)-Retinoic acid
All-trans Retinoic Acid
All-trans-Retinoate
All-trans-Retinoic acid
All-trans-Tretinoin
All-trans-Vitamin A acid
All-trans-Vitamin A1 acid
Alltrans-retinoic acid
Amnesteem
Atra-IV
Atragen
Atralin
Avita
Avita (TN)
Avita Gel
Avitoin
Avitoin [Norway]
BAL4079
BIDD:GT0483
BIDD:PXR0081
BML2-E05
BPBio1_000082
BRN 2057223
BSPBio_000074
BSPBio_001500
Betarretin
C00777
CCRIS 3294
CCRIS 7098
CHEBI:15367
CHEMBL38
CID444795
CPD000058245
Claravis
Cordes VAS [Germany]
Cordes vas
D00094
D014212
DB00523
DB00755
DB00982
Dermairol
EINECS 206-129-0
EU-0101061
Effederm
Effederm [France]
Epi-aberel
Eudyna
HMS1361K22
HMS1568D16
HMS1791K22
HMS1921D14
HMS1989K22
HMS2089D20
HMS2092N11
HMS502N05
HSDB 2169
HSDB 7186
I04-0008
I14-2351
IDI1_000903
IDI1_033970
Isotretinoin Retinoic acid
L000833
LGD 100057
LMPR01090019
LS-1154
Lopac0_001061
Lsotretinoin
MLS000028588
MLS001076515
MLS002207234
MLS002222211
MolPort-000-883-857
NCGC00017280-06
NCGC00017280-17
NCGC00021808-04
 
NCGC00021808-05
NCGC00021808-06
NCGC00021808-07
NCGC00021808-09
NCGC00021808-14
NCGC00021808-15
NSC 122758
NSC-122758
NSC122758
Nexret
Obagi
PDT-002-002
Panretin Gel
Panretyn
Potassium Salt, Tretinoin
Prestwick2_000257
Prestwick3_000257
Prestwick_424
R 2625
R0064
R2625_SIGMA
REA
RETINOIC ACID, ALL TRANS
RETINOIC acid
Refissa
Renova
Renova (TN)
Retacnyl
Retin A
Retin A (TN)
Retin-A
Retin-A Micro
Retin-a
Retin-a Micro
Retinoate
Retinoic acid
Retinoic acid, all-trans- (8CI)
Retinova
Retionic Acid
Retionic acid
Retisol-A
Retisol-a
Ro 1-5488
S1653_Selleck
SAM002264647
SMR000058245
SPECTRUM1502016
SR-01000000239
SR-01000000239-14
ST057075
Salt, Tretinoin Potassium
Salt, Tretinoin Sodium
Salt, Tretinoin Zinc
Sodium Salt, Tretinoin
Solage
Sotret
Spectrum5_001746
Spectrum5_001933
Stieva-A
Stieva-a
Stieva-a Forte
TRETINON
Tretin M
Tretin m
Tretin-x
Tretin.x
Tretinoin
Tretinoin (JAN/USP/INN)
Tretinoin (TN)
Tretinoin 0.1% cream or placebo
Tretinoin Cream
Tretinoin Gel Microsphere
Tretinoin Potassium Salt
Tretinoin Sodium Salt
Tretinoin Zinc Salt
Tretinoin [USAN:INN:BAN]
Tretinoin/All-Trans Retinoic Acid
Tretinoina
Tretinoina [INN-Spanish]
Tretinoine
Tretinoine (French)
Tretinoine (french) (einecs)
Tretinoine [INN-French]
Tretinoino
Tretinoino [INN-Spanish]
Tretinoinum
Tretinoinum [INN-Latin]
Tretinx
Tri-Luma
Trétinoïne
UNII-1UA8E65KDZ
UNII-5688UTC01R
UPCMLD-DP097
Vesanoid
Vesanoid (TN)
Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin
Vesnaroid
Vitamin A acid
Vitinoin
WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1
Zinc Salt, Tretinoin
[3H]Retinoic acid
all trans-Retinoic acid
all-(E)-Retinoic acid
all-(e)-Retinoic acid
all-trans-Retinoic acid
all-trans-Tretinoin
all-trans-Vitamin A acid
all-trans-Vitamin A1 acid
all-trans-Vitamin a acid
all-trans-Vitamin a1 acid
all-trans-b-Retinoic acid
all-trans-beta-Retinoic acid
b-Retinoic acid
beta all trans Retinoic Acid
beta-Ra
beta-Retinoate
beta-Retinoic Acid
beta-Retinoic acid
beta-all-trans-Retinoic acid
bmse000562
nchembio.154-comp2
trans Retinoic Acid
trans-Retinoate
trans-Retinoic acid
tretinoin
tretinoin liposome
tretinoine (French) (EINECS)
7
AcetylcholineexperimentalPhase 468951-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
Miochol E
O-Acetylcholine
acetylcholine chloride
8Dermatologic AgentsPhase 4, Phase 24555
9Protective AgentsPhase 4, Phase 35651
10
HydroquinonePhase 433123-31-9785
Synonyms:
1,4-Benzenediol
1,4-Dihydroxy-benzeen
1,4-Dihydroxy-benzol
1,4-Dihydroxybenzen
1,4-Diidrobenzene
4-Hydroxyphenol
Benzene-1,4-diol
Benzohydroquinone
Benzoquinol
Dihydroquinone
Dihydroxybenzene
Hydrochinon
Hydrochinone
Hydroquinol
Hydroquinole
Hydroquinone
Hydroquinone for synthesis
 
Hydroquinone gr
Hydroquinoue
Idrochinone
Melanex
Phiaquin
Quinol
Solaquin forte
a-Hydroquinone
alpha-Hydroquinone
b-Quinol
beta-Quinol
p-Benzenediol
p-Dihydroxybenzene
p-Dioxobenzene
p-Dioxybenzene
p-Hydroquinone
p-Hydroxybenzene
p-Hydroxyphenol
11AnalgesicsPhase 4, Phase 29358
12Radiation-Protective AgentsPhase 4333
13Analgesics, Non-NarcoticPhase 4, Phase 25184
14Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 118483
15Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 110422
16AbobotulinumtoxinAPhase 4588
17Antirheumatic AgentsPhase 4, Phase 2, Phase 18496
18Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 23549
19Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 19988
20Calcineurin InhibitorsPhase 4, Phase 3, Phase 21223
21Neurotransmitter AgentsPhase 414795
22OnabotulinumtoxinAPhase 4588
23Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 218510
24Neuromuscular AgentsPhase 4922
25IncobotulinumtoxinAPhase 4599
26Botulinum ToxinsPhase 4616
27Botulinum Toxins, Type APhase 4588
28Cholinergic AgentsPhase 43243
29HormonesPhase 4, Phase 2, Phase 3, Phase 111748
30HylanPhase 446
31AntioxidantsPhase 42442
32Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 38478
33glucocorticoidsPhase 4, Phase 2, Phase 33896
34Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 110002
35AmotosalenPhase 4, Phase 216
36mometasone furoatePhase 414483919-23-7
37Anti-Asthmatic AgentsPhase 42796
38Anti-Allergic AgentsPhase 41312
39Bronchodilator AgentsPhase 42377
40FurocoumarinsPhase 4, Phase 219
41FicusinPhase 4, Phase 215
42
FluticasonePhase 458990566-53-3, 80474-14-262924, 22833648
Synonyms:
90566-53-3
AC-456
AC1NSJZT
Asmatil
Axotide
BIDD:GT0819
Brethal
C07815
CHEMBL1201396
CID5311101
Cultivate
Cutivate
D07981
Flixonase
Flixonase Nasal Spray
Flixotide
Flixotide Disk
 
Flixotide Disks
Flixotide Inhaler
Flonase
Flovent
Flovent Diskus
Flovent Rotadisk
Fluinol
Flunase
Flusonal
Fluspiral
Fluticaps
Fluticaps (TN)
Fluticasone (INN)
Fluticasonpropionat Allen
Flutide
Flutivate
MolPort-006-666-449
S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
fluticasone
43Respiratory System AgentsPhase 43931
44Pharmaceutical SolutionsPhase 4, Phase 27004
45
TriamcinoloneapprovedPhase 2, Phase 3448124-94-731307
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9α-fluoro-16α-hydroxyprednisolone
AC-2072
AC1L1LDH
AC1Q5HJC
Adcortyl
Allernaze
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
Bio-0662
C21H27FO6
CHEMBL1451
CID31307
CL 19823
Celeste
Cinolone
Cinolone-T
D00385
D014221
DB00620
Delphicort
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-AG
Kenacort-Ag
Kenalog
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
LS-698
Ledercort
Lopac0_001179
MLS000028542
MLS001066543
 
MLS002695935
MolPort-002-528-981
Mycolog
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
NCI60_000750
NSC 13397
NSC13397
Nasacort
Nasacort Aq
Nasacort Hfa
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Prestwick_438
Rodinolone
S1933_Selleck
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
Sk-Triamcinolone
T6376_SIGMA
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Tri-Nasal
Triacet
Triacort
Triam-Tablinen
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
Triamcinolone (JP15/USP/INN)
Triamcinolone Acetonide
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Trianex
Triatex
Tricortale
Triderm
Triesence
Trilone
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
droxypregna-1,4-diene-3,20-dione
ione
nchembio.2007.53-comp7
triamcinolone
46Diuretics, Potassium SparingPhase 31445
47Sodium Channel BlockersPhase 31180
48Central Nervous System DepressantsPhase 310016
49Anti-Arrhythmia AgentsPhase 32371
50AnestheticsPhase 2, Phase 37385

Interventional clinical trials:

(show top 50)    (show all 72)
idNameStatusNCT IDPhase
1Botulinum Toxin Treatment for Localized VitiligoCompletedNCT01051687Phase 4
2Safety Study of Cosmetic Tissue Augmentation in People of ColorCompletedNCT01147172Phase 4
3A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.CompletedNCT00293163Phase 4
4Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of MelasmaCompletedNCT00469183Phase 4
5Post Market Safety Study and Effectiveness With Evolence in Subjects With Skin Color Types IV-VICompletedNCT00891774Phase 4
6Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active VitiligoRecruitingNCT01246921Phase 4
7Randomized, Split-body, Single-blinded Clinical Trial of NB-UVB Treatment for VitiligoRecruitingNCT02506101Phase 4
8Punchgrafting Techniques for VitiligoRecruitingNCT01377077Phase 4
9NB-UVB and PUVA Vitiligo StudyRecruitingNCT01732965Phase 4
10Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)RecruitingNCT01082393Phase 4
11Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult VitiligoActive, not recruitingNCT01333410Phase 4
12Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism PatientsActive, not recruitingNCT01640678Phase 4
13Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism PatientsEnrolling by invitationNCT02458417Phase 4
14Topical Bimatoprost Solution 0.03%in Stable VitiligoWithdrawnNCT01202513Phase 4
15Vitiligo Skin TransplantationCompletedNCT00830713Phase 3
16Epidermal Cell Transplantation in Vitiligo SkinCompletedNCT01629979Phase 2, Phase 3
17Vitiligo Treated With TL01 Combined With Tacrolimus Ointment Versus PlaceboCompletedNCT00807690Phase 3
18Excimer Lamp Versus Excimer Laser in Vitiligo TreatmentCompletedNCT00696358Phase 3
19Autologous Transplantation of Melanocytes for Treatment of Vitiligo SkinCompletedNCT00631865Phase 3
20Interest of the Dermabrasion by Laser Erbium in the Treatment of the VitiligoCompletedNCT01087216Phase 2, Phase 3
21Emervel Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and FoldsCompletedNCT01205061Phase 3
22Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of VitiligoRecruitingNCT02191748Phase 2, Phase 3
23Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITACRecruitingNCT02466997Phase 3
24Virus Early Transcription Factor (VETF) Multicenter Phototherapy ProtocolRecruitingNCT00525395Phase 3
25A Multicenter Trial of Non-cultured Epidermal Cellular Grafting Versus Hyaluronic Acid for Repigmenting Stable Leukoderma (Vitiligo and Piebaldism)RecruitingNCT02156427Phase 3
26A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)RecruitingNCT02608450Phase 3
27Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus ControlTerminatedNCT01841008Phase 2, Phase 3
28Efficacy and Safety of ACH24 in the Treatment of VitiligoWithdrawnNCT01419964Phase 3
29Comparative Study of Techniques in Melanocyte-Keratinocyte Transplantation for the Treatment of VitiligoWithdrawnNCT01822379Phase 2, Phase 3
30Clinical Trial of Simvastatin to Treat Generalized VitiligoCompletedNCT01517893Phase 2
31Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental VitiligoCompletedNCT01382589Phase 2
32Melanocyte Transplantation for Patients With Stable Vitiligo.CompletedNCT01701648Phase 1, Phase 2
33Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of VitiligoCompletedNCT01511965Phase 1, Phase 2
34Study of the Efficacy and Safety of Etanercept in Adults With VitiligoCompletedNCT00134368Phase 2
35Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo VulgarisCompletedNCT00372307Phase 2
36Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in PatientsCompletedNCT00928902Phase 2
37Efficacy of Red Light in VitiligoRecruitingNCT01787708Phase 2
38Efficacy and Safety of Intralesional Corticosterois in the Treatment of VitiligoRecruitingNCT01766609Phase 2
39Atorvastatin in Active VitiligoRecruitingNCT02432534Phase 2
40UVA 1 Phototherapy for VitiligoRecruitingNCT01787695Phase 2
41Treatment and Complication of Bath PUVA in VitiligoRecruitingNCT00380471Phase 2
42Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the HandRecruitingNCT01792245Phase 2
43Efficacy of Autologous Outer-Root-Sheath Melanocytes Transplantation in the Treatment of VitiligoTerminatedNCT01923142Phase 2
44A New Micrografting Technique for VitiligoTerminatedNCT01262547Phase 2
45Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in AdolescentsCompletedNCT00907062Phase 1
46Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)CompletedNCT01430195Phase 1
47Effect of Procedural Variables on Outcome of Surgical Treatment of VitiligoCompletedNCT02510651Phase 1
48Open-label Pilot Study of Abatacept for the Treatment of VitiligoRecruitingNCT02281058Phase 1
49Molecular Mechanisms of Helium-Neon Laser on Melanocyte Regeneration in Skin Equivalent Vitiligo ModelRecruitingNCT00172939Phase 1
50Photocil (Topical) for the Treatment of VitiligoCompletedNCT01992185

Search NIH Clinical Center for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Inferred drug relations via UMLS65/NDF-RT43:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:
JACE
Embryonic/Adult Cultured Cells Related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:
Cultured epidermis (JACE, PMIDs: 23265935, 17465819, 11987545


Cochrane evidence based reviews: vitiligo

Genetic Tests for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

Anatomical Context for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

MalaCards organs/tissues related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

33
Skin, Eye, Retina, Thyroid

Animal Models for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 or affiliated genes

About this section

MGI Mouse Phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

38 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020069.4AIRE, CAT, KITLG, POMC, TYR, TYRP1
2MP:00053798.6AIRE, CD8A, CTLA4, KITLG, MITF, POMC
3MP:00053978.0AIRE, CD8A, CTLA4, KITLG, MITF, NLRP1
4MP:00053917.8AIRE, DCT, DDC, KITLG, MITF, PAH
5MP:00036317.6AIRE, CD8A, DCT, DDC, KITLG, MCHR1
6MP:00011867.6CTLA4, DCT, KITLG, MITF, MLANA, PAH
7MP:00053787.6AIRE, DDC, KITLG, MCHR1, MITF, PAH
8MP:00107687.5AIRE, CAT, CD8A, CTLA4, DDC, KITLG
9MP:00053877.4AIRE, CD8A, CTLA4, DDC, KITLG, MITF
10MP:00107717.3CD8A, CTLA4, DCT, KITLG, MITF, MLANA
11MP:00053766.6AIRE, CAT, CTLA4, DDC, KITLG, MCHR1

Publications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

Variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

UniProtKB/Swiss-Prot genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

67
id Symbol AA change Variation ID SNP ID
1NLRP1p.Leu155HisVAR_033239rs12150220
2PTPN22p.Arg620TrpVAR_022605rs2476601

Clinvar genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

5
id Gene Variation Type Significance SNP ID Assembly Location
1NLRP1NM_001033053.2(NLRP1): c.464T> A (p.Leu155His)single nucleotide variantrisk factorrs12150220GRCh37Chr 17, 5485367: 5485367

Expression for genes affiliated with Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section
Search GEO for disease gene expression data for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1.

Pathways for genes affiliated with Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

GO Terms for genes affiliated with Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

Biological processes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1tetrahydrobiopterin biosynthetic processGO:000672910.4GCH1, PCBD1
2pigmentationGO:004347310.2DCT, TYRP1
3cellular nitrogen compound metabolic processGO:00346419.3DCT, DDC, PAH, TYR
4oxidation-reduction processGO:00551149.3CAT, PAH, TPO, TYRP1

Sources for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet